Posted on Sep 30, 2025
Efficient LC-MS/MS Bioanalysis with Minimal Optimization
September 30, 2025
Author: Our Phenomenex Team
Phenomenex has unveiled a powerful new tool for bioanalytical scientists working with oligonucleotide therapeutics: Clarity OTX Pro, a next-generation solid phase extraction (SPE) kit designed to simplify and standardize sample preparation for LC-MS/MS workflows.
As oligo-based drugs and conjugates gain traction in therapeutic development, researchers face mounting pressure to improve extraction efficiency and data reliability. Traditional methods often require extensive optimization and still yield inconsistent results. Clarity OTX Pro was developed to address these pain points—delivering high recovery rates, cleaner extracts, and consistent performance across complex biological matrices.
“With our original method, we saw poor peak shape and lost resolution,” said Ian Dawson, Principal Method Development Scientist at Agilex Bio. “Using Clarity OTX Pro, chromatography is excellent, and we achieved ~90% recovery without needing to tweak the method.”
Key Benefits of Clarity OTX Pro for Oligo Bioanalysis:
- High-performance extraction for oligonucleotides and oligo-conjugates.
- Minimal method development required—ideal for fast-paced labs.
- Improved reproducibility and reduced day-to-day variability.
- Optimized for LC-MS/MS, ensuring better data quality and confidence in results.
This SPE kit is a game-changer for scientists seeking reliable, scalable solutions for oligonucleotide bioanalysis. Whether you're working in early-stage drug discovery or regulated bioanalytical environments, Clarity OTX Pro helps streamline workflows and reduce time spent troubleshooting extraction protocols.
Phenomenex continues to lead in chromatography innovation, offering tools that support the advancement of biotherapeutics and empower researchers to make informed decisions with confidence.
Explore the full capabilities of Clarity OTX Pro and connect with our technical team on Chat or visit Clarity OTX Pro.
